Athenex Announces Acceptance of Oral Paclitaxel Phase II Study in Angiosarcoma Abstract at ASCO20 Virtual Scientific Program

BUFFALO, N.Y., April 29, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that an abstract for its ongoing Phase II study of oral paclitaxel and encequidar (Oral Paclitaxel; formerly known as Oraxol), for the treatment of angiosarcoma, has been accepted for presentation in a poster discussion session at the American Society of Clinical Oncology’s (ASCO) upcoming ASCO20 Virtual Scientific Program, to be held from May 29 to May 31, 2020.

Presentation details are as follows:

• Title: (Abstract 11517) A Phase II Study of Oraxol in the Treatment of Unresectable Cutaneous Angiosarcoma
• Poster Session: Sarcoma
• Location: ASCO Virtual Scientific Program

This Phase II study is an ongoing, single arm study evaluating the activity, safety and tolerability of oral paclitaxel (205 mg/m²) with encequidar administered orally, once daily, for 3 consecutive days per week in patients with cutaneous angiosarcoma (clinicaltrials.gov identifier: NCT03544567).

The abstract title is currently available on the ASCO Meeting Library, with the full abstract scheduled to be published on May 13, 2020, at 5:00 PM EDT.

The Orascovery platform was initially developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi.

About Angiosarcoma
Angiosarcomas are a type of soft tissue sarcoma characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood and lymphatic vessels. Angiosarcomas arise in various body sites, including cutaneous, soft tissue, and visceral locations. Angiosarcomas are frequently metastatic at diagnosis, with a natural history complicated by local recurrence, distant metastases, and poor overall survival. There is no approved treatment for angiosarcoma and survival is limited with treatments currently available. However, reports in the literature of objective tumor response support the use of intravenous paclitaxel in the treatment of angiosarcoma.